Latest Pearl Therapeutics Stories
REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Pearl Therapeutics announced today the appointment of Chuck Bramlage to the position of president and chief executive officer. In addition, Mr. Bramlage will join the Company's Board of Directors.
REDWOOD CITY, Calif., May 18 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).
- Withering but not falling off, as a blossom that persists on a twig after flowering.